Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Philips to Collaborate on MDx Platform

NEW YORK (GenomeWeb News) – Epigenomics today said that it has signed a collaboration and licensing agreement with Royal Philips Electronics to develop a molecular diagnostics platform for running cancer tests.
 
The firms will jointly perform feasibility studies aimed at developing a fully automated instrument platform for diagnosing certain cancers based on DNA methylation biomarkers.
 
As part of the pact, Philips obtained the option to license the technologies and biomarkers separately or in combination for diagnostic applications. The Dutch electronics and medical imaging equipment firm may exercise the option upon successful completion of the feasibility studies, said Epigenomics.
 
Financial details of the agreement were not disclosed.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.